Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. CCH:LN
3. META
4. CCHGY
5. PRY:IM
6. PRYMY
7. SPY
8. SKA-B
9. PBA
10. ALAR

Go back to Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM

Bristol-Myers Squibb (BMY) Files Mixed Shelf Registration Statement

December 13, 2021 4:35 PM EST

Bristol-Myers Squibb (NYSE: BMY) has filed mixed shelf of:
DEBT SECURITIES
PREFERRED STOCK
DEPOSITARY SHARES
COMMON STOCK
WARRANTS

... More